References
- Shields CL, Demirci H, Karatza E, et al. Clinical Survey of 1643 melanocytic and nonmelanocytic conjunctival tumours. Ophthalmology 2004; 111:1747–1754.
- Shields CL, Markowitz JS, Belinsky I, Shields JA. Conjuctival melanoma: Outcomes based on tumour origin in 382 consecutive cases. Ophthalmology 2011; 118:389–395.
- Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: Risks for progression to melanoma in 311 Eyes. Ophthalmology 2008; 115:511–519.
- Folberg R, McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol 1985; 16:129–135.
- De Potter P, Shields CL, Shields JA. Malignant melanoma of the conjunctiva. Int Ophthalmol Clin 1993; 33:25–30.
- Finger PT, Milner MS, McCormick SA. Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol 1993; 77:751–753.
- Baron S, Tyring SK, Fleischmann RJ, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991; 266:1375–1383.
- Decatris M, Santhanam S, O’Byrne K. Potential of interferon alpha in solid tumours: part 1. BioDrugs 2002; 16:261–281.
- Santhanam S, Decatris M, O’Byrne K. Potential of interferon alpha in solid tumours: part 2. BioDrugs 2002; 16:349–372.
- Hanley JP, Haydon GH. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leuk Lymphoma 1998; 29:257–268.
- Sekar V, Atmar VJ, Joshi AR, et al. Inhibition of ornithine decarboxylase in human fibroblast cells by type I and type II interferons. Biochem Biophys Res Commun 1983; 114:950–954.
- Fleischmann WRJ, Newton RC, Fleischmann CM, et al. Discrimination between non-malignant and malignant cells by combinations by IFN γ and IFN α/β. J Biol Response Mod 1984; 3:397–405.
- Fuchsluger TA, Hintschich C, Steuhl KP, Meller D. Adjuvant topical interferon alpha-2b treatment in epithelial tumours of the ocular surface. Ophthalmologe 2006;103:124–128.
- Boehm MD, Huang AJ. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology 2004; 111:1755–1761.
- Herold TR, Hintschich C. Interferon-alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol 2010; 248:111–115.
- Edge SB, Byrd DR, Compton CC, et al. Carcinoma of the conjunctiva. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010. pp. 531–537.
- Jakobiec FA, Rini FJ, Fraunfelder FT, Brownstein S. Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma: experience with 62 cases. Ophthalmology. 1988; 95:1058–1070.
- Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol 2008; 145:124–129.
- Fujioka M, Sakamoto M, Azumi A, et al. A case of conjunctival malignant melanoma treated with subconjunctival injection of interferon beta efficacy and side effects. Nippon Ganka Gakkai Zasshi 2006; 110:51–57.
- Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumour Regression in Association With Modulation of Tumour Infiltrating Host Cellular Immune Responses. J Clin Oncol 2006; 24:3164–3167.
- Wang W, Edington HD, Rao UNM, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007; 13:1523–1531.
- Bromberg JF, Horvarth CM, Wen Z, et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon-alpha and interferon- gamma. Proc Natl Acad Sci USA 1996; 93:7673–7678.
- Brassard DL, Grace MJ, Bordens RW. Interferon-α as an immunotherapeutic protein. J Leukoc Biol 2002; 71:565–581.